Evaluation of symptom relief, nasal airflow, nasal cytology, and acceptability of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis

Ann Allergy. 1990 Jun;64(6):536-40.


A new formulation of intranasal flunisolide containing less propylene glycol was compared with the original formulation for efficacy and acceptability in more than 200 patients with symptoms of perennial allergic rhinitis. In this multicenter, randomized, double-blind, parallel group study, symptomatic patients were treated with either the new or the original formulation of 0.025% solution of intranasal flunisolide for 4 weeks to provide 200 micrograms flunisolide daily. Both formulations were highly effective in decreasing symptom scores as evident from patient diary reports before and after treatment (P less than .001). Similarly, nasal airflow was improved with each treatment as measured by anterior rhinomanometry (P less than .0002) and the number of patients with nasal eosinophilia decreased (P less than .01). Finally, fewer patients using the new formulation reported nasal burning or stinging and the acceptability rating of the new formulation was higher.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / therapeutic use
  • Dosage Forms
  • Double-Blind Method
  • Fluocinolone Acetonide / administration & dosage
  • Fluocinolone Acetonide / analogs & derivatives*
  • Fluocinolone Acetonide / therapeutic use
  • Humans
  • Middle Aged
  • Multicenter Studies as Topic
  • Nose / drug effects*
  • Patient Acceptance of Health Care
  • Randomized Controlled Trials as Topic
  • Rhinitis, Allergic, Perennial / drug therapy*


  • Anti-Inflammatory Agents
  • Dosage Forms
  • Fluocinolone Acetonide
  • flunisolide